Ception adds $14.7M to big third round

Malvern, PA-based Ception Therapeutics has ginned an additional $14.7 million in its third round, bringing the total amount raised in the round to $77 million. Third Point and Greenlight Capital were among the investors. The company's pipeline includes a late-stage biologic agent in clinical development for multiple inflammatory conditions, a small molecule anti-TNF program and other discovery programs.

"The support we've received from our current investors provides validation of our business model and the value of Ception's portfolio of assets," said Steve Tullman, president and CEO.

- here's the release on the latest round

Related Article:
Ception Therapeutics pockets $63M in third round. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.